Table 3.
Breast cancer serum autoantibody biomarkers
| Analysis | Function | Marker | Cases/controls | Sensitivity | Specificity | Reference |
|---|---|---|---|---|---|---|
| Apoptosis | SURVIVIN | 46/10 | 24% | - | [12,195] | |
| LIVIN | 46/10 | 33% | - | |||
| P53 | 165/230 | 7%-21% | 95%-100% | [12,64,93,146,181] | ||
| 165/0 | ||||||
| 144/242 | ||||||
| Single Markers | ANNEXIN XIA | 90/51 | 19%(PBC) (60%DCIS) |
98% | [60] | |
| Growth | RPA32 | 801165 | 11% | 100% | [177] | |
| Signaling | SPAG9 | 94 | 80% | - | [82] | |
| HER2 | 107/200 | 11% | 100% | [20,46] | ||
| Adhesion | CYCLOPHILIN | 28/21 | 86% | 52% | [170] | |
| Other | GLOBOH | 58/47 | 58% | 73% | [185] | |
| FXBP52 | 142/93 | - | 95% | [44] | ||
| PPIA | ||||||
| PRDX2 | ||||||
| HPSO | ||||||
| MUCI | ||||||
| AAb Panel | ASB-9 | 87/87 | 80% | 100% | [197] | |
| SERACI | ||||||
| RELT | ||||||
| BRCAI | 133/94 | 64%(PBC) | 85% | [31] | ||
| C-MYC | 45%(DCIS) | |||||
| HER2 | ||||||
| MUCI | ||||||
| NY-ESOI | ||||||
| P53 | ||||||
| BRCA2 | ||||||
| P53 mutants | 55/8 | 16% | 100% | [15] | ||
| C-MYC | 64/82 | 77%-92% | 85%-91% | [83] | ||
| CYCLINBI | ||||||
| IMPI | ||||||
| KOC | ||||||
| P53 | ||||||
| P62 | ||||||
| SURVIVIN |
PBC: Primary Breast Carcinoma; DCIS: Ductal Carcinoma In Situ.